Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Translational Medicine Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Cancer Lett. 2016 Apr 28;374(1):107-116. doi: 10.1016/j.canlet.2016.01.032. Epub 2016 Jan 22.
In this study we tried to systematically investigate the tumor suppressing microRNAs in ccRCC.
The MTS cell viability and colony formation assay were used to systematically detect the tumor suppressing ability of down-regulated miRNAs in ccRCC. Then miR-206 expression was detected by RT-qPCR and in situ hybridization in ccRCC cell lines and clinical samples. Oligonucleotides were used to overexpress or down-regulate miR-206. MTS cell viability, EdU cell proliferation, colony formation assay, flow cytometry, Xenograft subcutaneously and orthotopic implantations were done to examine tumor suppressing effects of miR-206 in vitro and in vivo. Luciferase assay was performed to verify the precise target of miR-206.
We reviewed and experimentally analyzed the currently available miRNA expression profiles data of ccRCC and identified miR-206 as one of the most critical tumor-suppressing microRNAs in ccRCC. In addition, miR-206 inhibited ccRCC cell proliferation through inducing cell cycle arrest by directly targeting cell cycle related gene CDK4, CDK9 and CCND1.
All these results suggested that miR-206 functioned as a novel cell cycle regulator and tumor suppressor in ccRCC and could be considered as a potential target for ccRCC therapy.
本研究旨在系统研究 ccRCC 中的肿瘤抑制性 microRNAs。
采用 MTS 细胞活力和集落形成实验系统检测 ccRCC 下调 microRNAs 的肿瘤抑制能力。然后通过 RT-qPCR 和原位杂交检测 ccRCC 细胞系和临床样本中的 miR-206 表达。使用寡核苷酸过表达或下调 miR-206。进行 MTS 细胞活力、EdU 细胞增殖、集落形成实验、流式细胞术、皮下和原位移植,以体外和体内检测 miR-206 的肿瘤抑制作用。进行荧光素酶实验以验证 miR-206 的精确靶标。
我们回顾并实验分析了目前可用的 ccRCC miRNA 表达谱数据,确定 miR-206 是 ccRCC 中最关键的肿瘤抑制 microRNAs 之一。此外,miR-206 通过直接靶向细胞周期相关基因 CDK4、CDK9 和 CCND1 诱导细胞周期停滞来抑制 ccRCC 细胞增殖。
所有这些结果表明,miR-206 在 ccRCC 中作为一种新型细胞周期调节剂和肿瘤抑制因子发挥作用,可被视为 ccRCC 治疗的潜在靶点。